Functionalized materials for multistage platforms in the oral delivery of biopharmaceuticals

Progress in Materials Science

Volumn 89, Issue , 2017, Pages 306-344

  Araújo, Francisca ^a,b,c,d   das Neves, José ^a,b   Martins, João Pedro ^d   Granja, Pedro L ^a,b,c   Santos, Hélder A ^d   Sarmento, Bruno ^a,b,e  

^a UNIVERSITY OF PORTO   (Portugal)

^b INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF HELSINKI   (Finland)

^e INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

Author keywords

Biomaterials; Biopharmaceuticals; Multistage platforms; Oral delivery; Surface functionalization

Indexed keywords

BIOCOMPATIBILITY; BIOLOGICAL MATERIALS; BIOMATERIALS; CONTROLLED DRUG DELIVERY; DRUG PRODUCTS; INTERFACES (MATERIALS);

BIOPHARMACEUTICAL PRODUCTS; BIOPHARMACEUTICALS; DRUG DELIVERY SYSTEM; FUNCTIONALIZED MATERIALS; MULTISTAGE PLATFORMS; ORAL DELIVERY; PARTICULATE DELIVERY SYSTEMS; SURFACE FUNCTIONALIZATION;

TARGETED DRUG DELIVERY;

EID: 85020029869     PISSN: 00796425     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmatsci.2017.05.001     Document Type: Review

References (395)

1. Nitta, S.K., Numata, K., Biopolymer-based nanoparticles for drug/gene delivery and tissue engineering. Int J Mol Sci 14 (2013), 1629–1654.
2. Pellegrini, S., Cantarelli, E., Sordi, V., Nano, R., Piemonti, L., The state of the art of islet transplantation and cell therapy in type 1 diabetes. Acta Diabetol 53 (2016), 683–691.
3. Tian, H., Tang, Z., Zhuang, X., Chen, X., Jing, X., Biodegradable synthetic polymers: preparation, functionalization and biomedical application. Prog Polym Sci 37 (2012), 237–280.
4. Moyano, D.F., Rotello, V.M., Nano meets biology: structure and function at the nanoparticle interface. Langmuir 27 (2011), 10376–10385.
5. Morishita, M., Peppas, N.A., Is the oral route possible for peptide and protein drug delivery?. Drug Discov Today 11 (2006), 905–910.
6. Araújo, F., Shrestha, N., Shahbazi, M.A., Fonte, P., Mäkilä, E.M., Salonen, J.J., et al. The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium. Biomaterials 35 (2014), 9199–9207.
7. Shrestha, N., Shahbazi, M.A., Araujo, F., Zhang, H., Makila, E.M., Kauppila, J., et al. Chitosan-modified porous silicon microparticles for enhanced permeability of insulin across intestinal cell monolayers. Biomaterials 35 (2014), 7172–7179.
8. Chen, M.C., Mi, F.L., Liao, Z.X., Hsiao, C.W., Sonaje, K., Chung, M.F., et al. Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules. Adv Drug Deliv Rev 65 (2013), 865–879.
9. Sarti, F., Iqbal, J., Muller, C., Shahnaz, G., Rahmat, D., Bernkop-Schnurch, A., Poly(acrylic acid)-cysteine for oral vitamin B12 delivery. Anal Biochem 420 (2012), 13–19.
10. Valencia, P.M., Pridgen, E.M., Rhee, M., Langer, R., Farokhzad, O.C., Karnik, R., Microfluidic platform for combinatorial synthesis and optimization of targeted nanoparticles for cancer therapy. ACS Nano 7 (2013), 10671–10680.
11. Gao, W., Chan, J.M., Farokhzad, O.C., pH-responsive nanoparticles for drug delivery. Mol Pharm 7 (2010), 1913–1920.
12. You, J.-O., Almeda, D., Ye, G.J., Auguste, D.T., Bioresponsive matrices in drug delivery. J Biol Eng 4 (2010), 1–13.
13. De, M., Rana, S., Akpinar, H., Miranda, O.R., Arvizo, R.R., Bunz, U.H., et al. Sensing of proteins in human serum using conjugates of nanoparticles and green fluorescent protein. Nat Chem 1 (2009), 461–465.
14. Subbiah, R., Veerapandian, M., Yun, K.S., Nanoparticles: functionalization and multifunctional applications in biomedical sciences. Curr Med Chem 17 (2010), 4559–4577.
15. Boisselier, E., Astruc, D., Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem Soc Rev 38 (2009), 1759–1782.
16. Tang, W., Becker, M.L., “Click” reactions: a versatile toolbox for the synthesis of peptide-conjugates. Chem Soc Rev 43 (2014), 7013–7039.
17. Mout, R., Moyano, D.F., Rana, S., Rotello, V.M., Surface functionalization of nanoparticles for nanomedicine. Chem Soc Rev 41 (2012), 2539–2544.
18. Martinez, J.O., Brown, B.S., Quattrocchi, N., Evangelopoulos, M., Ferrari, M., Tasciotti, E., Multifunctional to multistage delivery systems: the evolution of nanoparticles for biomedical applications. Chin Sci Bull 57 (2012), 3961–3971.
19. Serda, R.E., Godin, B., Blanco, E., Chiappini, C., Ferrari, M., Multi-stage delivery nano-particle systems for therapeutic applications. Biochem Biophys Acta 1810 (2011), 317–329.
20. Date, A.A., Hanes, J., Ensign, L.M., Nanoparticles for oral delivery: design, evaluation and state-of-the-art. J Control Release: Off J Control Release Soc, 2016.
21. Pérez, Y., Urista, C., Martínez, J., Nava, M., Rodríguez, F., Functionalized polymers for enhance oral bioavailability of sensitive molecules. Polymers, 8, 2016, 214.
22. Swierczewska, M., Han, H.S., Kim, K., Park, J.H., Lee, S., Polysaccharide-based nanoparticles for theranostic nanomedicine. Adv Drug Deliv Rev 99 (2016), 70–84.
23. Amidon, G.L., Lennernas, H., Shah, V.P., Crison, J.R., A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12 (1995), 413–420.
24. Dahan, A., Miller, J.M., Amidon, G.L., Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. AAPS J 11 (2009), 740–746.
25. Lobenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm: Off J Arbeitsgemeinschaft Pharmazeutische Verfahrenstechnik eV 2000;50:3–12.
26. Martinez, M.N., Amidon, G.L., A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol 42 (2002), 620–643.
27. Shugarts, S., Benet, L.Z., The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res 26 (2009), 2039–2054.
28. Sosnik, A., das Neves, J., Sarmento, B., Mucoadhesive polymers in the design of nano-drug delivery systems for administration by non-parenteral routes: a review. Prog Polym Sci 39 (2014), 2030–2075.
29. Lai, S.K., Wang, Y.-Y., Hanes, J., Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 61 (2009), 158–171.
30. Greaves, J.L., Wilson, C.G., Treatment of diseases of the eye with mucoadhesive delivery systems. Adv Drug Deliv Rev 11 (1993), 349–383.
31. Schreiber, S., Scheid, P., Gastric mucus of the guinea pig: proton carrier and diffusion barrier. Am J Physiol 272 (1997), G63–G70.
32. Lai, S.K., Wang, Y.Y., Hanes, J., Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 61 (2009), 158–171.
33. Mucosal delivery of biopharmaceuticals – biology, challenges and strategies. US: Springer; 2014.
34. Yang, C., Chilvers, M., Montgomery, M., Nolan, S.J., Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev, 4, 2016, CD001127.
35. Gupta, S., Jain, A., Chakraborty, M., Sahni, J.K., Ali, J., Dang, S., Oral delivery of therapeutic proteins and peptides: a review on recent developments. Drug Deliv 20 (2013), 237–246.
36. Araujo, F., Shrestha, N., Granja, P.L., Hirvonen, J., Santos, H.A., Sarmento, B., Safety and toxicity concerns of orally delivered nanoparticles as drug carriers. Expert Opin Drug Metab Toxicol 11 (2015), 381–393.
37. Chen, M.C., Sonaje, K., Chen, K.J., Sung, H.W., A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials 32 (2011), 9826–9838.
38. Araujo, F., Fonte, P., Santos, H.A., Sarmento, B., Oral delivery of glucagon-like peptide-1 and analogs: alternatives for diabetes control?. J Diab Sci Technol 6 (2012), 1486–1497.
39. Yun, Y., Cho, Y.W., Park, K., Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. Adv Drug Deliv Rev 65 (2013), 822–832.
40. Rekha, M.R., Sharma, C.P., Oral delivery of therapeutic protein/peptide for diabetes – future perspectives. Int J Pharm 440 (2013), 48–62.
41. Roger, E., Lagarce, F., Garcion, E., Benoit, J.P., Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine (Lond) 5 (2010), 287–306.
42. Ensign, L.M., Cone, R., Hanes, J., Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev 64 (2012), 557–570.
43. Cone, R.A., Barrier properties of mucus. Adv Drug Deliv Rev 61 (2009), 75–85.
44. Johansson, M.E., Ambort, D., Pelaseyed, T., Schutte, A., Gustafsson, J.K., Ermund, A., et al. Composition and functional role of the mucus layers in the intestine. Cell Mol Life Sci 68 (2011), 3635–3641.
45. Thornton, D.J., Sheehan, J.K., From mucins to mucus: toward a more coherent understanding of this essential barrier. Proc Am Thorac Soc 1 (2004), 54–61.
46. das Neves, J., Bahia, M.F., Amiji, M.M., Sarmento, B., Mucoadhesive nanomedicines: characterization and modulation of mucoadhesion at the nanoscale. Expert Opin Drug Deliv 8 (2011), 1085–1104.
47. Renukuntla, J., Vadlapudi, A.D., Patel, A., Boddu, S.H., Mitra, A.K., Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm 447 (2013), 75–93.
48. Pawar, V.K., Meher, J.G., Singh, Y., Chaurasia, M., Surendar Reddy, B., Chourasia, M.K., Targeting of gastrointestinal tract for amended delivery of protein/peptide therapeutics: strategies and industrial perspectives. J Control Release: Off J Control Release Soc 196 (2014), 168–183.
49. Gerbe, F., Legraverend, C., Jay, P., The intestinal epithelium tuft cells: specification and function. Cell Mol Life Sci 69 (2012), 2907–2917.
50. Pridgen, E.M., Alexis, F., Farokhzad, O.C., Polymeric nanoparticle drug delivery technologies for oral delivery applications. Expert Opin Drug Deliv 12 (2015), 1459–1473.
51. Kristensen, M., Nielsen, H.M., Cell-penetrating peptides as carriers for oral delivery of biopharmaceuticals. Basic Clin Pharmacol Toxicol 118 (2016), 99–106.
52. Maroni, A., Zema, L., Del Curto, M.D., Foppoli, A., Gazzaniga, A., Oral colon delivery of insulin with the aid of functional adjuvants. Adv Drug Deliv Rev 64 (2012), 540–556.
53. Tsukita, S., Furuse, M., Itoh, M., Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2 (2001), 285–293.
54. Van Itallie, C.M., Holmes, J., Bridges, A., Gookin, J.L., Coccaro, M.R., Proctor, W., et al. The density of small tight junction pores varies among cell types and is increased by expression of claudin-2. J Cell Sci 121 (2008), 298–305.
55. Anderson, J.M., Van Itallie, C.M., Physiology and function of the tight junction. Cold Spring Harb Perspect Biol, 1, 2009, a002584.
56. Fonte, P., Araújo, F., Silva, C., Pereira, C., Reis, S., Santos, H.A., et al. Polymer-based nanoparticles for oral insulin delivery: revisited approaches. Biotechnol Adv 33 (2015), 1342–1354.
57. Solanki, A., Kim, J.D., Lee, K.B., Nanotechnology for regenerative medicine: nanomaterials for stem cell imaging. Nanomedicine (Lond) 3 (2008), 567–578.
58. Goldberg, M., Langer, R., Jia, X., Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Polym Ed 18 (2007), 241–268.
59. Beg, S., Rizwan, M., Sheikh, A.M., Hasnain, M.S., Anwer, K., Kohli, K., Advancement in carbon nanotubes: basics, biomedical applications and toxicity. J Pharm Pharmacol 63 (2011), 141–163.
60. Ambrogio, M.W., Thomas, C.R., Zhao, Y.-L., Zink, J.I., Stoddart, J.F., Mechanized silica nanoparticles: a new frontier in theranostic nanomedicine. Acc Chem Res 44 (2011), 903–913.
61. Salonen, J., Kaukonen, A.M., Hirvonen, J., Lehto, V.P., Mesoporous silicon in drug delivery applications. J Pharm Sci 97 (2008), 632–653.
62. Hillyer, J.F., Albrecht, R.M., Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles. J Pharm Sci 90 (2001), 1927–1936.
63. Kumari, M., Rajak, S., Singh, S.P., Murty, U.S., Mahboob, M., Grover, P., et al. Biochemical alterations induced by acute oral doses of iron oxide nanoparticles in Wistar rats. Drug Chem Toxicol 36 (2013), 296–305.
64. Weissleder, R., Kelly, K., Sun, E.Y., Shtatland, T., Josephson, L., Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol 23 (2005), 1418–1423.
65. Wilczewska, A.Z., Niemirowicz, K., Markiewicz, K.H., Car, H., Nanoparticles as drug delivery systems. Pharmacol Rep 64 (2012), 1020–1037.
66. Lopes, C.M., Bettencourt, C., Rossi, A., Buttini, F., Barata, P., Overview on gastroretentive drug delivery systems for improving drug bioavailability. Int J Pharm, 2016.
67. Plapied, L., Duhem, N., des Rieux, A., Préat, V., Fate of polymeric nanocarriers for oral drug delivery. Curr Opin Colloid Interface Sci 16 (2011), 228–237.
68. Wagner, V., Dullaart, A., Bock, A.-K., Zweck, A., The emerging nanomedicine landscape. Nat Biotechnol 24 (2006), 1211–1217.
69. Silva, G.A., Ducheyne, P., Reis, R.L., Materials in particulate form for tissue engineering. 1. Basic concepts. J Tissue Eng Regen Med 1 (2007), 4–24.
70. Moulari, B., Beduneau, A., Pellequer, Y., Lamprecht, A., Nanoparticle targeting to inflamed tissues of the gastrointestinal tract. Curr Drug Deliv 10 (2013), 9–17.
71. Nam, J., Won, N., Bang, J., Jin, H., Park, J., Jung, S., et al. Surface engineering of inorganic nanoparticles for imaging and therapy. Adv Drug Deliv Rev 65 (2013), 622–648.
72. Leitner, V.M., Walker, G.F., Bernkop-Schnürch, A., Thiolated polymers: evidence for the formation of disulphide bonds with mucus glycoproteins. Eur J Pharm Biopharm 56 (2003), 207–214.
73. Arseneault, M., Wafer, C., Morin, J.F., Recent advances in click chemistry applied to dendrimer synthesis. Molecules 20 (2015), 9263–9294.
74. John, J.V., Johnson, R.P., Heo, M.S., Moon, B.K., Byeon, S.J., Kim, I., Polymer-block-polypeptides and polymer-conjugated hybrid materials as stimuli-responsive nanocarriers for biomedical applications. J Biomed Nanotechnol 11 (2015), 1–39.
75. Kolb, H.C., Finn, M.G., Sharpless, K.B., Click chemistry: diverse chemical function from a few good reactions. Angew Chem Int Ed Engl 40 (2001), 2004–2021.
76. Hein, C.D., Liu, X.M., Wang, D., Click chemistry, a powerful tool for pharmaceutical sciences. Pharm Res 25 (2008), 2216–2230.
77. Lallana, E., Fernandez-Trillo, F., Sousa-Herves, A., Riguera, R., Fernandez-Megia, E., Click chemistry with polymers, dendrimers, and hydrogels for drug delivery. Pharm Res 29 (2012), 902–921.
78. Lallana, E., Sousa-Herves, A., Fernandez-Trillo, F., Riguera, R., Fernandez-Megia, E., Click chemistry for drug delivery nanosystems. Pharm Res 29 (2012), 1–34.
79. Nandivada, H., Jiang, X., Lahann, J., Click chemistry: versatility and control in the hands of materials scientists. Adv Mater 19 (2007), 2197–2208.
80. Xi, W., Scott, T.F., Kloxin, C.J., Bowman, C.N., Click chemistry in materials science. Adv Func Mater 24 (2014), 2572–2590.
81. Chen, Y., Xianyu, Y., Wu, J., Yin, B., Jiang, X., Click chemistry-mediated nanosensors for biochemical assays. Theranostics 6 (2016), 969–985.
82. Li, N., Binder, W.H., Click-chemistry for nanoparticle-modification. J Mater Chem 21 (2011), 16717–16734.
83. Singh, A., Bezuidenhout, M., Walsh, N., Beirne, J., Felletti, R., Wang, S., et al. Functionalization of emissive conjugated polymer nanoparticles by coprecipitation: consequences for particle photophysics and colloidal properties. Nanotechnology, 27, 2016, 305603.
84. Martien, R., Loretz, B., Thaler, M., Majzoob, S., Bernkop-Schnurch, A., Chitosan-thioglycolic acid conjugate: an alternative carrier for oral nonviral gene delivery?. J Biomed Mater Res A 82 (2007), 1–9.
85. Chalasani, K.B., Russell-Jones, G.J., Jain, A.K., Diwan, P.V., Jain, S.K., Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. J Control Release 122 (2007), 141–150.
86. Madaan, K., Kumar, S., Poonia, N., Lather, V., Pandita, D., Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues. J Pharm Bioall Sci 6 (2014), 139–150.
87. Tomalia, D.A., Baker, H., Dewald, J., Hall, M., Kallos, G., Martin, S., et al. A new class of polymers: starburst-dendritic macromolecules. Polym J 17 (1985), 117–132.
88. Tomalia, D.A., Naylor, A.M., Goddard, W.A., Starburst dendrimers: molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter. Angew Chem, Int Ed Engl 29 (1990), 138–175.
89. Sadekar, S., Ghandehari, H., Transepithelial transport and toxicity of PAMAM dendrimers: implications for oral drug delivery. Adv Drug Deliv Rev 64 (2012), 571–588.
90. Sadekar, S., Thiagarajan, G., Bartlett, K., Hubbard, D., Ray, A., McGill, L.D., et al. Poly(amido amine) dendrimers as absorption enhancers for oral delivery of camptothecin. Int J Pharm 456 (2013), 175–185.
91. Santos, C., Mateus, M.L., dos Santos, A.P., Moreira, R., de Oliveira, E., Gomes, P., Cyclization-activated prodrugs. Synthesis, reactivity and toxicity of dipeptide esters of paracetamol. Bioorg Med Chem Lett 15 (2005), 1595–1598.
92. Schulz, F., Vossmeyer, T., Bastus, N.G., Weller, H., Effect of the spacer structure on the stability of gold nanoparticles functionalized with monodentate thiolated poly(ethylene glycol) ligands. Langmuir 29 (2013), 9897–9908.
93. Doane, T., Burda, C., Nanoparticle mediated non-covalent drug delivery. Adv Drug Deliv Rev 65 (2013), 607–621.
94. des Rieux, A., Pourcelle, V., Cani, P.D., Marchand-Brynaert, J., Preat, V., Targeted nanoparticles with novel non-peptidic ligands for oral delivery. Adv Drug Deliv Rev 65 (2013), 833–844.
95. Fonte, P., Nogueira, T., Gehm, C., Ferreira, D., Sarmento, B., Chitosan-coated solid lipid nanoparticles enhance the oral absorption of insulin. Drug Deliv Transl Res 1 (2011), 299–308.
96. Sheng, J., He, H., Han, L., Qin, J., Chen, S., Ru, G., et al. Enhancing insulin oral absorption by using mucoadhesive nanoparticles loaded with LMWP-linked insulin conjugates. J Control Release 233 (2016), 181–190.
97. Nel, A.E., Madler, L., Velegol, D., Xia, T., Hoek, E.M., Somasundaran, P., et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 8 (2009), 543–557.
98. Gaumet, M., Vargas, A., Gurny, R., Delie, F., Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm 69 (2008), 1–9.
99. Gaumet, M., Gurny, R., Delie, F., Localization and quantification of biodegradable particles in an intestinal cell model: the influence of particle size. Eur J Pharm Sci 36 (2009), 465–473.
100. Shinde Patil, V.R., Campbell, C.J., Yun, Y.H., Slack, S.M., Goetz, D.J., Particle diameter influences adhesion under flow. Biophys J 80 (2001), 1733–1743.
101. Byrne, J.D., Betancourt, T., Brannon-Peppas, L., Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60 (2008), 1615–1626.
102. Tuma, P., Hubbard, A.L., Transcytosis: crossing cellular barriers. Physiol Rev 83 (2003), 871–932.
103. Martins, J.P., Kennedy, P.J., Santos, H.A., Barrias, C., Sarmento, B., A comprehensive review of the neonatal Fc receptor and its application in drug delivery. Pharmacol Ther 161 (2016), 22–39.
104. des Rieux, A., Fievez, V., Théate, I., Mast, J., Préat, V., Schneider, Y.-J., An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. Eur J Pharm Sci 30 (2007), 380–391.
105. Bourganis, V., Karamanidou, T., Samaridou, E., Karidi, K., Kammona, O., Kiparissides, C., On the synthesis of mucus permeating nanocarriers. Eur J Pharm Biopharm: Off J Arbeitsgemeinschaft Pharmazeutische Verfahrenstechnik eV 97 (2015), 239–249.
106. Griffin, B.T., Guo, J., Presas, E., Donovan, M., Alonso, M.J., O'Driscoll, C.M., Pharmacokinetic, pharmacodynamic and biodistribution following oral administration of nanocarriers containing peptide and protein drugs. Adv Drug Deliv Rev, 2016.
107. Zhao, F., Zhao, Y., Liu, Y., Chang, X., Chen, C., Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small 7 (2011), 1322–1337.
108. Hirsch, V., Kinnear, C., Moniatte, M., Rothen-Rutishauser, B., Clift, M.J., Fink, A., Surface charge of polymer coated SPIONs influences the serum protein adsorption, colloidal stability and subsequent cell interaction in vitro. Nanoscale 5 (2013), 3723–3732.
109. Kaaki, K., Herve-Aubert, K., Chiper, M., Shkilnyy, A., Souce, M., Benoit, R., et al. Magnetic nanocarriers of doxorubicin coated with poly(ethylene glycol) and folic acid: relation between coating structure, surface properties, colloidal stability, and cancer cell targeting. Langmuir 28 (2012), 1496–1505.
110. Rahme, K., Chen, L., Hobbs, R.G., Morris, M.A., O'Driscoll, C., Holmes, J.D., PEGylated gold nanoparticles: polymer quantification as a function of PEG lengths and nanoparticle dimensions. RSC Adv 3 (2013), 6085–6094.
111. Cho, E.C., Xie, J., Wurm, P.A., Xia, Y., Understanding the role of surface charges in cellular adsorption versus internalization by selectively removing gold nanoparticles on the cell surface with a I2/KI etchant. Nano Lett 9 (2009), 1080–1084.
112. das Neves, J., Michiels, J., Arien, K.K., Vanham, G., Amiji, M., Bahia, M.F., et al. Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine. Pharm Res 29 (2012), 1468–1484.
113. Yu, T., Malugin, A., Ghandehari, H., Impact of silica nanoparticle design on cellular toxicity and hemolytic activity. ACS Nano 5 (2011), 5717–5728.
114. Zhang, X., Sun, M., Zheng, A., Cao, D., Bi, Y., Sun, J., Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration. Eur J Pharm Sci 45 (2012), 632–638.
115. Araújo, F., Shrestha, N., Granja, P.L., Hirvonen, J., Santos, H.A., Sarmento, B., Antihyperglycemic potential of incretins orally delivered via nano and microsystems and subsequent glucoregulatory effects. Curr Pharm Biotechnol 15 (2014), 609–619.
116. Verma, A., Stellacci, F., Effect of surface properties on nanoparticle-cell interactions. Small 6 (2010), 12–21.
117. Hosseininasab, S., Pashaei-Asl, R., Khandaghi, A.A., Nasrabadi, H.T., Nejati-Koshki, K., Akbarzadeh, A., et al. Synthesis, characterization, and in vitro studies of PLGA-PEG nanoparticles for oral insulin delivery. Chem Biol Drug Des 84 (2014), 307–315.
118. Chaturvedi, K., Ganguly, K., Kulkarni, A.R., Rudzinski, W.E., Krauss, L., Nadagouda, M.N., et al. Oral insulin delivery using deoxycholic acid conjugated PEGylated polyhydroxybutyrate co-polymeric nanoparticles. Nanomedicine (Lond) 10 (2015), 1569–1583.
119. Pierri, E., Avgoustakis, K., Poly(lactide)-poly(ethylene glycol) micelles as a carrier for griseofulvin. J Biomed Mater Res A 75 (2005), 639–647.
120. Zastre, J., Jackson, J., Bajwa, M., Liggins, R., Iqbal, F., Burt, H., Enhanced cellular accumulation of a P-glycoprotein substrate, rhodamine-123, by caco-2 cells using low molecular weight methoxypolyethylene glycol-block-polycaprolactone diblock copolymers. Eur J Pharm Biopharm 54 (2002), 299–309.
121. Zhang, X., Chen, G., Zhang, T., Ma, Z., Wu, B., Effects of PEGylated lipid nanoparticles on the oral absorption of one BCS II drug: a mechanistic investigation. Int J Nanomed 9 (2014), 5503–5514.
122. Yuan, H., Chen, C.Y., Chai, G.H., Du, Y.Z., Hu, F.Q., Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles. Mol Pharm 10 (2013), 1865–1873.
123. Xu, Q., Ensign, L.M., Boylan, N.J., Schon, A., Gong, X., Yang, J.C., et al. Impact of surface polyethylene glycol (PEG) density on biodegradable nanoparticle transport in mucus ex vivo and distribution in vivo. ACS Nano 9 (2015), 9217–9227.
124. Maisel, K., Ensign, L., Reddy, M., Cone, R., Hanes, J., Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse. J Control Release: Off J Control Release Soc 197 (2015), 48–57.
125. Crater, J.S., Carrier, R.L., Barrier properties of gastrointestinal mucus to nanoparticle transport. Macromol Biosci 10 (2010), 1473–1483.
126. Veronese, F.M., Pasut, G., PEGylation, successful approach to drug delivery. Drug Discov Today 10 (2005), 1451–1458.
127. Champion, J.A., Katare, Y.K., Mitragotri, S., Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J Control Release: Off J Control Release Soc 121 (2007), 3–9.
128. Amin, M.L., Joo, J.Y., Yi, D.K., An, S.S., Surface modification and local orientations of surface molecules in nanotherapeutics. J Control Release: Off J Control Release Soc 207 (2015), 131–142.
129. Chithrani, B.D., Chan, W.C., Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett 7 (2007), 1542–1550.
130. Toy, R., Peiris, P.M., Ghaghada, K.B., Karathanasis, E., Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles. Nanomedicine (Lond) 9 (2014), 121–134.
131. Dasgupta, S., Auth, T., Gompper, G., Shape and orientation matter for the cellular uptake of nonspherical particles. Nano Lett 14 (2014), 687–693.
132. Caldorera-Moore, M., Guimard, N., Shi, L., Roy, K., Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers. Expert Opin Drug Deliv 7 (2010), 479–495.
133. Florez, L., Herrmann, C., Cramer, J.M., Hauser, C.P., Koynov, K., Landfester, K., et al. How shape influences uptake: interactions of anisotropic polymer nanoparticles and human mesenchymal stem cells. Small 8 (2012), 2222–2230.
134. Zhang, Y., Tekobo, S., Tu, Y., Zhou, Q., Jin, X., Dergunov, S.A., et al. Permission to enter cell by shape: nanodisk vs nanosphere. ACS Appl Mater Interfaces 4 (2012), 4099–4105.
135. Dunne, M., Corrigan, I., Ramtoola, Z., Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. Biomaterials 21 (2000), 1659–1668.
136. Panyam, J., Dali, M.M., Sahoo, S.K., Ma, W., Chakravarthi, S.S., Amidon, G.L., et al. Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. J Control Release: Off J Control Release Soc 92 (2003), 173–187.
137. Niu, Y., Yu, M., Hartono, S.B., Yang, J., Xu, H., Zhang, H., et al. Nanoparticles mimicking viral surface topography for enhanced cellular delivery. Adv Mater 25 (2013), 6233–6237.
138. Agueros, M., Areses, P., Campanero, M.A., Salman, H., Quincoces, G., Penuelas, I., et al. Bioadhesive properties and biodistribution of cyclodextrin-poly(anhydride) nanoparticles. Eur J Pharm Sci 37 (2009), 231–240.
139. Muheem, A., Shakeel, F., Jahangir, M.A., Anwar, M., Mallick, N., Jain, G.K., et al. A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives. Saudi Pharm J 24 (2016), 413–428.
140. Khutoryanskiy, V.V., Advances in mucoadhesion and mucoadhesive polymers. Macromol Biosci 11 (2011), 748–764.
141. Andrews, G.P., Laverty, T.P., Jones, D.S., Mucoadhesive polymeric platforms for controlled drug delivery. Eur J Pharm Biopharm: Off J Arbeitsgemeinschaft Pharmazeutische Verfahrenstechnik eV 71 (2009), 505–518.
142. Deat-Laine, E., Hoffart, V., Garrait, G., Jarrige, J.F., Cardot, J.M., Subirade, M., et al. Efficacy of mucoadhesive hydrogel microparticles of whey protein and alginate for oral insulin delivery. Pharm Res 30 (2013), 721–734.
143. Yang, J.-S., Xie, Y.-J., He, W., Research progress on chemical modification of alginate: a review. Carbohyd Polym 84 (2011), 33–39.
144. Li, Y., Zhao, H., Duan, L.-R., Li, H., Yang, Q., Tu, H.-H., et al. Preparation, characterization and evaluation of bufalin liposomes coated with citrus pectin. Colloids Surf, A 444 (2014), 54–62.
145. Gungor, S., Okyar, A., Erturk-Toker, S., Baktir, G., Ozsoy, Y., Ondansetron-loaded chitosan microspheres for nasal antiemetic drug delivery: an alternative approach to oral and parenteral routes. Drug Dev Ind Pharm 36 (2010), 806–813.
146. Sharma, R., Ahuja, M., Kaur, H., Thiolated pectin nanoparticles: preparation, characterization and ex vivo corneal permeation study. Carbohyd Polym 87 (2012), 1606–1610.
147. Makhlof, A., Werle, M., Tozuka, Y., Takeuchi, H., A mucoadhesive nanoparticulate system for the simultaneous delivery of macromolecules and permeation enhancers to the intestinal mucosa. J Control Release: Off J Control Release Soc 149 (2011), 81–88.
148. Kriwet, B., Walter, E., Kissel, T., Synthesis of bioadhesive poly(acrylic acid) nano- and microparticles using an inverse emulsion polymerization method for the entrapment of hydrophilic drug candidates. J Control Release: Off J Control Release Soc 56 (1998), 149–158.
149. Rahmat, D., Muller, C., Barthelmes, J., Shahnaz, G., Martien, R., Bernkop-Schnurch, A., Thiolated hydroxyethyl cellulose: design and in vitro evaluation of mucoadhesive and permeation enhancing nanoparticles. Eur J Pharm Biopharm: Off J Arbeitsgemeinschaft Pharmazeutische Verfahrenstechnik eV 83 (2013), 149–155.
150. Suwannateep, N., Banlunara, W., Wanichwecharungruang, S.P., Chiablaem, K., Lirdprapamongkol, K., Svasti, J., Mucoadhesive curcumin nanospheres: biological activity, adhesion to stomach mucosa and release of curcumin into the circulation. J Control Release: Off J Control Release Soc 151 (2011), 176–182.
151. Takeuchi, H., Yamamoto, H., Kawashima, Y., Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev 47 (2001), 39–54.
152. Prego, C., Garcia, M., Torres, D., Alonso, M.J., Transmucosal macromolecular drug delivery. J Control Release: Off J Control Release Soc 101 (2005), 151–162.
153. Andrade, F., Antunes, F., Nascimento, A.V., da Silva, S.B., das Neves, J., Ferreira, D., et al. Chitosan formulations as carriers for therapeutic proteins. Curr Drug Discov Technol 8 (2011), 157–172.
154. Sigurdsson, H.H., Loftsson, T., Lehr, C.M., Assessment of mucoadhesion by a resonant mirror biosensor. Int J Pharm 325 (2006), 75–81.
155. Smart, J.D., The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev 57 (2005), 1556–1568.
156. Pearson, J.P., Chater, P.I., Wilcox, M.D., The properties of the mucus barrier, a unique gel – how can nanoparticles cross it?. Ther Deliv 7 (2016), 229–244.
157. Bajka, B.H., Rigby, N.M., Cross, K.L., Macierzanka, A., Mackie, A.R., The influence of small intestinal mucus structure on particle transport ex vivo. Colloids Surf, B 135 (2015), 73–80.
158. Tang, B.C., Dawson, M., Lai, S.K., Wang, Y.Y., Suk, J.S., Yang, M., et al. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc Natl Acad Sci USA 106 (2009), 19268–19273.
159. Yang, M., Lai, S.K., Wang, Y.Y., Zhong, W., Happe, C., Zhang, M., et al. Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus. Angew Chem Int Ed Engl 50 (2011), 2597–2600.
160. Thirawong, N., Thongborisute, J., Takeuchi, H., Sriamornsak, P., Improved intestinal absorption of calcitonin by mucoadhesive delivery of novel pectin-liposome nanocomplexes. J Control Release: Off J Control Release Soc 125 (2008), 236–245.
161. Kollner, S., Dunnhaupt, S., Waldner, C., Hauptstein, S., Pereira de Sousa, I., Bernkop-Schnurch, A., Mucus permeating thiomer nanoparticles. Eur J Pharm Biopharm: Off J Arbeitsgemeinschaft Pharmazeutische Verfahrenstechnik eV 97 (2015), 265–272.
162. Yildiz, H.M., McKelvey, C.A., Marsac, P.J., Carrier, R.L., Size selectivity of intestinal mucus to diffusing particulates is dependent on surface chemistry and exposure to lipids. J Drug Target 23 (2015), 768–774.
163. Shrestha, N., Shahbazi, M.A., Araujo, F., Makila, E., Raula, J., Kauppinen, E.I., et al. Multistage pH-responsive mucoadhesive nanocarriers prepared by aerosol flow reactor technology: a controlled dual protein-drug delivery system. Biomaterials 68 (2015), 9–20.
164. Miller, C.R., Bondurant, B., McLean, S.D., McGovern, K.A., O'Brien, D.F., Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry 37 (1998), 12875–12883.
165. Netsomboon, K., Bernkop-Schnurch, A., Mucoadhesive vs. mucopenetrating particulate drug delivery. Eur J Pharm Biopharm: Off J Arbeitsgemeinschaft Pharmazeutische Verfahrenstechnik eV 98 (2016), 76–89.
166. Perera, G., Zipser, M., Bonengel, S., Salvenmoser, W., Bernkop-Schnurch, A., Development of phosphorylated nanoparticles as zeta potential inverting systems. Eur J Pharm Biopharm: Off J Arbeitsgemeinschaft Pharmazeutische Verfahrenstechnik eV 97 (2015), 250–256.
167. Bonengel, S., Prufert, F., Perera, G., Schauer, J., Bernkop-Schnurch, A., Polyethylene imine-6-phosphogluconic acid nanoparticles–a novel zeta potential changing system. Int J Pharm 483 (2015), 19–25.
168. Muller, C., Perera, G., Konig, V., Bernkop-Schnurch, A., Development and in vivo evaluation of papain-functionalized nanoparticles. Eur J Pharm Biopharm: Off J Arbeitsgemeinschaft Pharmazeutische Verfahrenstechnik eV 87 (2014), 125–131.
169. Pereira de Sousa, I., Cattoz, B., Wilcox, M.D., Griffiths, P.C., Dalgliesh, R., Rogers, S., et al. Nanoparticles decorated with proteolytic enzymes, a promising strategy to overcome the mucus barrier. Eur J Pharm Biopharm: Off J Arbeitsgemeinschaft Pharmazeutische Verfahrenstechnik eV 97 (2015), 257–264.
170. Colombo, P., Sonvico, F., Colombo, G., Bettini, R., Novel platforms for oral drug delivery. Pharm Res 26 (2009), 601–611.
171. Karimi M, Eslami M, Sahandi-Zangabad P, Mirab F, Farajisafiloo N, Shafaei Z, et al. pH-sensitive stimulus-responsive nanocarriers for targeted delivery of therapeutic agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2016.
172. Yoshida, T., Lai, T.C., Kwon, G.S., Sako, K., PH- and ion-sensitive polymers for drug delivery. Expert Opin Drug Deliv 10 (2013), 1497–1513.
173. Balamuralidhara, V., Pramodkumar, T.M., Srujana, N., Venkatesh, M.P., Gupta, N.V., Krishna, K.L., et al. PH sensitive drug delivery systems: a review. Am J Drug Discov Develop 1 (2011), 24–48.
174. Lowman, A.M., Morishita, M., Kajita, M., Nagai, T., Peppas, N.A., Oral delivery of insulin using pH-responsive complexation gels. J Pharm Sci, 88, 1999.
175. Peppas, N.A., Devices based on intelligent biopolymers for oral protein delivery. Int J Pharm 277 (2004), 11–17.
176. Sharma, M., Sharma, V., Panda, A.K., Majumdar, D.K., Development of enteric submicron particle formulation of papain for oral delivery. Int J Nanomed 6 (2011), 2097–2111.
177. Jelvehgari, M., Zakeri-Milani, P., Siahi-Shadbad, M.R., Loveymi, B.D., Nokhodchi, A., Azari, Z., et al. Development of pH-sensitive insulin nanoparticles using Eudragit L100-55 and chitosan with different molecular weights. AAPS PharmSciTech 11 (2010), 1237–1242.
178. Sun, S., Liang, N., Yamamoto, H., Kawashima, Y., Cui, F., Yan, P., pH-sensitive poly(lactide-co-glycolide) nanoparticle composite microcapsules for oral delivery of insulin. Int J Nanomed 10 (2015), 3489–3498.
179. Araujo, F., Shrestha, N., Shahbazi, M.A., Liu, D., Herranz-Blanco, B., Makila, E.M., et al. Microfluidic assembly of a multifunctional tailorable composite system designed for site specific combined oral delivery of peptide drugs. ACS Nano 9 (2015), 8291–8302.
180. Araújo, F., Shrestha, N., Gomes, M.J., Herranz-Blanco, B., Liu, D., Hirvonen, J.J., et al. In vivo dual-delivery of glucagon like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP4) inhibitor through composites prepared by microfluidics for diabetes therapy. Nanoscale 8 (2016), 10706–10713.
181. Liu, D., Herranz-Blanco, B., Mäkilä, E., Arriaga, L.R., Mirza, S., Weitz, D.A., et al. Microfluidic templated mesoporous silicon-solid lipid microcomposites for sustained drug delivery. ACS Appl Mater Interfaces 5 (2013), 12127–12134.
182. Herranz-Blanco, B., Ginestar, E., Zhang, H., Hirvonen, J., Santos, H.A., Microfluidics platform for glass capillaries and its application in droplet and nanoparticle fabrication. Int J Pharm 516 (2017), 100–105.
183. Shrestha, N., Araujo, F., Shahbazi, M.A., Makila, E., Gomes, M.J., Airavaara, M., et al. Oral hypoglycaemic effect of GLP-1 and DPP4 inhibitor based nanocomposites in a diabetic animal model. J Control Release: Off J Control Release Soc 232 (2016), 113–119.
184. Hsieh, P.W., Hung, C.F., Fang, J.Y., Current prodrug design for drug discovery. Curr Pharm Des 15 (2009), 2236–2250.
185. Vaidya, A., Jain, S., Agrawal, R.K., Jain, S.K., Pectin–metronidazole prodrug bearing microspheres for colon targeting. J Saudi Chem Soc 19 (2015), 257–264.
186. Li, M.G., Lu, W.L., Wang, J.C., Zhang, X., Zhang, H., Wang, X.Q., et al. Preparation and characterization of insulin nanoparticles employing chitosan and poly(methylmethacrylate/methylmethacrylic acid) copolymer. J Nanosci Nanotechnol 6 (2006), 2874–2886.
187. Jarvinen, K., Akerman, S., Svarfvar, B., Tarvainen, T., Viinikka, P., Paronen, P., Drug release from pH and ionic strength responsive poly(acrylic acid) grafted poly(vinylidenefluoride) membrane bags in vitro. Pharm Res, 15, 1998.
188. Sonaje, K., Lin, K.J., Wey, S.P., Lin, C.K., Yeh, T.H., Nguyen, H.N., et al. Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: oral delivery using pH-responsive nanoparticles vs. subcutaneous injection. Biomaterials 31 (2010), 6849–6858.
189. Sonaje, K., Lin, K.J., Wang, J.J., Mi, F.L., Chen, C.T., Juang, J.H., et al. Self-assembled pH-sensitive nanoparticles: a platform for oral delivery of protein drugs. Adv Func Mater 20 (2010), 3695–3700.
190. Sonaje, K., Chen, Y.J., Chen, H.L., Wey, S.P., Juang, J.H., Nguyen, H.N., et al. Enteric-coated capsules filled with freeze-dried chitosan/poly(gamma-glutamic acid) nanoparticles for oral insulin delivery. Biomaterials 31 (2010), 3384–3394.
191. Mukhopadhyay, P., Chakraborty, S., Bhattacharya, S., Mishra, R., Kundu, P.P., pH-sensitive chitosan/alginate core-shell nanoparticles for efficient and safe oral insulin delivery. Int J Biol Macromol 72 (2015), 640–648.
192. Chen, S.C., Wu, Y.C., Mi, F.L., Lin, Y.H., Yu, L.C., Sung, H.W., A novel pH-sensitive hydrogel composed of N,O-carboxymethyl chitosan and alginate cross-linked by genipin for protein drug delivery. J Control Release: Off J Control Release Soc 96 (2004), 285–300.
193. Li, L.L., Chen, D., Zhang, Y.Q., Deng, Z.T., Ren, X.L., Meng, X.W., et al. Magnetic and fluorescent multifunctional chitosan nanoparticles as a smart drug delivery system. Nanotechnology, 18, 2007.
194. de Moura, M.R., Aouada, F.A., Mattoso, L.H., Preparation of chitosan nanoparticles using methacrylic acid. J Colloid Interface Sci 321 (2008), 477–483.
195. González-Flecha B, Demple B. Biochemistry of redox signaling in the activation of oxidative stress genes. Reactive oxygen species in biological systems: an interdisciplinary approach. Boston, MA: Springer, US; 2002. p. 133–53.
196. Sun, Y., Oberley, L.W., Redox regulation of transcriptional activators. Free Radic Biol Med 21 (1996), 335–348.
197. Schafer, F.Q., Buettner, G.R., Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 30 (2001), 1191–1212.
198. Remant, B.K., Chandrashekaran, V., Cheng, B., Chen, H., Pena, M.M., Zhang, J., et al. Redox potential ultrasensitive nanoparticle for the targeted delivery of camptothecin to HER2-positive cancer cells. Mol Pharm 11 (2014), 1897–1905.
199. Huo, M., Yuan, J., Tao, L., Wei, Y., Redox-responsive polymers for drug delivery: from molecular design to applications. Polym Chem 5 (2014), 1519–1528.
200. Zhao, M., Biswas, A., Hu, B., Joo, K.I., Wang, P., Gu, Z., et al. Redox-responsive nanocapsules for intracellular protein delivery. Biomaterials 32 (2011), 5223–5230.
201. Vong, L.B., Tomita, T., Yoshitomi, T., Matsui, H., Nagasaki, Y., An orally administered redox nanoparticle that accumulates in the colonic mucosa and reduces colitis in mice. Gastroenterology, 143(1027–36), 2012, e3.
202. des Rieux, A., Fievez, V., Garinot, M., Schneider, Y.J., Preat, V., Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release: Off J Control Release Soc 116 (2006), 1–27.
203. Wong, N.A., Herriot, M., Rae, F., An immunohistochemical study and review of potential markers of human intestinal M cells. Eur J Histochem 47 (2003), 143–150.
204. Clark, M.A., Jepson, M.A., Hirst, B.H., Exploiting M cells for drug and vaccine delivery. Adv Drug Deliv Rev 50 (2001), 81–106.
205. Wang, C., Ho, P.C., Lim, L.Y., Wheat germ agglutinin-conjugated PLGA nanoparticles for enhanced intracellular delivery of paclitaxel to colon cancer cells. Int J Pharm 400 (2010), 201–210.
206. Pielage, J.F., Cichon, C., Greune, L., Hirashima, M., Kucharzik, T., Schmidt, M.A., Reversible differentiation of Caco-2 cells reveals galectin-9 as a surface marker molecule for human follicle-associated epithelia and M cell-like cells. Int J Biochem Cell Biol 39 (2007), 1886–1901.
207. D'Souza, B., Bhowmik, T., Shashidharamurthy, R., Oettinger, C., Selvaraj, P., D'Souza, M., Oral microparticulate vaccine for melanoma using M-cell targeting. J Drug Target 20 (2012), 166–173.
208. Rajapaksa, T.E., Stover-Hamer, M., Fernandez, X., Eckelhoefer, H.A., Lo, D.D., Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery. J Control Release: Off J Control Release Soc 142 (2010), 196–205.
209. Lo, D.D., Ling, J., Eckelhoefer, A.H., M cell targeting by a Claudin 4 targeting peptide can enhance mucosal IgA responses. BMC Biotechnol, 12, 2012, 7.
210. Mestecky, J., Michalek, S.M., Moldoveanu, Z., Russell, M.W., Routes of immunization and antigen delivery systems for optimal mucosal immune responses in humans. Behring Inst Mitt, 33–43, 1997.
211. Williams, N.A., Hirst, T.R., Nashar, T.O., Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic. Immunol Today 20 (1999), 95–101.
212. Fievez, V., Plapied, L., des Rieux, A., Pourcelle, V., Freichels, H., Wascotte, V., et al. Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination. Eur J Pharm Biopharm: Off J Arbeitsgemeinschaft Pharmazeutische Verfahrenstechnik eV 73 (2009), 16–24.
213. Harokopakis, E., Hajishengallis, G., Michalek, S.M., Effectiveness of liposomes possessing surface-linked recombinant B subunit of cholera toxin as an oral antigen delivery system. Infect Immun 66 (1998), 4299–4304.
214. Kyd, J.M., Cripps, A.W., Functional differences between M cells and enterocytes in sampling luminal antigens. Vaccine 26 (2008), 6221–6224.
215. Kim, S.-H., Lee, K.-Y., Jang, Y.-S., Mucosal immune system and M cell-targeting strategies for oral mucosal vaccination. Immune Netw 12 (2012), 165–175.
216. Mundargi, R.C., Babu, V.R., Rangaswamy, V., Patel, P., Aminabhavi, T.M., Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release 125 (2008), 193–209.
217. Zhang, N., Ping, Q.N., Huang, G.H., Xu, W.F., Investigation of lectin-modified insulin liposomes as carriers for oral administration. Int J Pharm 294 (2005), 247–259.
218. Youn, Y.S., Chae, S.Y., Lee, S., Kwon, M.J., Shin, H.J., Lee, K.C., Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation. Eur J Pharm Biopharm: Off J Arbeitsgemeinschaft Pharmazeutische Verfahrenstechnik eV 68 (2008), 667–675.
219. Simons, K., Fuller, S.D., Cell surface polarity in epithelia. Annu Rev Cell Biol 1 (1985), 243–288.
220. Roger, E., Kalscheuer, S., Kirtane, A., Guru, B.R., Grill, A.E., Whittum-Hudson, J., et al. Folic acid functionalized nanoparticles for enhanced oral drug delivery. Mol Pharm 9 (2012), 2103–2110.
221. Neal, M.D., Leaphart, C., Levy, R., Prince, J., Billiar, T.R., Watkins, S., et al. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J Immunol 176 (2006), 3070–3079.
222. Pridgen, E.M., Alexis, F., Kuo, T.T., Levy-Nissenbaum, E., Karnik, R., Blumberg, R.S., et al. Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor for oral delivery. Sci Transl Med, 2013, 5 213ra167.
223. Van den Broeck, W., Cox, E., Oudega, B., Goddeeris, B.M., The F4 fimbrial antigen of Escherichia coli and its receptors. Vet Microbiol 71 (2000), 223–244.
224. Melkebeek, V., Rasschaert, K., Bellot, P., Tilleman, K., Favoreel, H., Deforce, D., et al. Targeting aminopeptidase N, a newly identified receptor for F4ac fimbriae, enhances the intestinal mucosal immune response. Mucosal Immunol 5 (2012), 635–645.
225. Kang, S.K., Woo, J.H., Kim, M.K., Woo, S.S., Choi, J.H., Lee, H.G., et al. Identification of a peptide sequence that improves transport of macromolecules across the intestinal mucosal barrier targeting goblet cells. J Biotechnol 135 (2008), 210–216.
226. Jin, Y., Song, Y., Zhu, X., Zhou, D., Chen, C., Zhang, Z., et al. Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials 33 (2012), 1573–1582.
227. Xu, W., Ling, P., Zhang, T., Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. J Drug Deliv, 2013, 2013, 340315.
228. Bae, Y., Jang, W.D., Nishiyama, N., Fukushima, S., Kataoka, K., Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery. Mol BioSyst 1 (2005), 242–250.
229. Dufresne, M.-H., Gauthier, M.A., Leroux, J.-C., Thiol-functionalized polymeric micelles: from molecular recognition to improved mucoadhesion. Bioconjug Chem 16 (2005), 1027–1033.
230. Sudimack, J., Lee, R.J., Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 41 (2000), 147–162.
231. Aguirre, T.A., Teijeiro-Osorio, D., Rosa, M., Coulter, I.S., Alonso, M.J., Brayden, D.J., Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials. Adv Drug Deliv Rev, 2016.
232. Rao KK. Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides. Google Patents; 2008.
233. Aungst, B.J., Absorption enhancers: applications and advances. AAPS J 14 (2012), 10–18.
234. Maher, S., Mrsny, R.J., Brayden, D.J., Intestinal permeation enhancers for oral peptide delivery. Adv Drug Deliv Rev, 2016.
235. Kondoh, M., Yagi, K., Progress in absorption enhancers based on tight junction. Expert Opin Drug Deliv 4 (2007), 275–286.
236. Maher, S., Leonard, T.W., Jacobsen, J., Brayden, D.J., Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. Adv Drug Deliv Rev 61 (2009), 1427–1449.
237. Scott Swenson, E., Curatolo, W.J., Penetration enhancement for polypeptides through epithelia (C) Means to enhance penetration. Adv Drug Deliv Rev 8 (1992), 39–92.
238. McCartney, F., Gleeson, J.P., Brayden, D.J., Safety concerns over the use of intestinal permeation enhancers: a mini-review. Tissue Barriers, 4, 2016, e1176822.
239. Park, K., Kwon, I.C., Park, K., Oral protein delivery: current status and future prospect. React Funct Polym 71 (2011), 280–287.
240. Aungst, B.J., Intestinal permeation enhancers. J Pharm Sci 89 (2000), 429–442.
241. Lee, J.H., Sahu, A., Choi, W.I., Lee, J.Y., Tae, G., ZOT-derived peptide and chitosan functionalized nanocarrier for oral delivery of protein drug. Biomaterials, 2016.
242. Lee, S., Lee, J., Lee, D.Y., Kim, S.K., Lee, Y., Byun, Y., A new drug carrier, Nalpha-deoxycholyl-L: -lysyl-methylester, for enhancing insulin absorption in the intestine. Diabetologia 48 (2005), 405–411.
243. Leone-Bay, A., Sato, M., Paton, D., Hunt, A.H., Sarubbi, D., Carozza, M., et al. Oral delivery of biologically active parathyroid hormone. Pharm Res 18 (2001), 964–970.
244. Shi, N.Q., Qi, X.R., Xiang, B., Zhang, Y., A survey on “Trojan Horse” peptides: opportunities, issues and controlled entry to “Troy”. J Control Release: Off J Control Release Soc 194 (2014), 53–70.
245. Palm-Apergi, C., Lorents, A., Padari, K., Pooga, M., Hallbrink, M., The membrane repair response masks membrane disturbances caused by cell-penetrating peptide uptake. FASEB J 23 (2009), 214–223.
246. Wang, F., Wang, Y., Zhang, X., Zhang, W., Guo, S., Jin, F., Recent progress of cell-penetrating peptides as new carriers for intracellular cargo delivery. J Control Release: Off J Control Release Soc 174 (2014), 126–136.
247. Guo, F., Zhang, M., Gao, Y., Zhu, S., Chen, S., Liu, W., et al. Modified nanoparticles with cell-penetrating peptide and amphipathic chitosan derivative for enhanced oral colon absorption of insulin: preparation and evaluation. Drug Deliv 23 (2016), 2003–2014.
248. Mahmood, A., Prufert, F., Efiana, N.A., Ashraf, M.I., Hermann, M., Hussain, S., et al. Cell-penetrating self-nanoemulsifying drug delivery systems (SNEDDS) for oral gene delivery. Expert Opin Drug Deliv, 2016.
249. Christiaens, B., Grooten, J., Reusens, M., Joliot, A., Goethals, M., Vandekerckhove, J., et al. Membrane interaction and cellular internalization of penetratin peptides. Eur J Biochem 271 (2004), 1187–1197.
250. Barany-Wallje, E., Keller, S., Serowy, S., Geibel, S., Pohl, P., Bienert, M., et al. A critical reassessment of penetratin translocation across lipid membranes. Biophys J 89 (2005), 2513–2521.
251. Ding, X., Rath, P., Angelo, R., Stringfellow, T., Flanders, E., Dinh, S., et al. Oral absorption enhancement of cromolyn sodium through noncovalent complexation. Pharm Res 21 (2004), 2196–2206.
252. Emisphere Technologies, Inc. Available URL: < http://www.emisphere.com/eligen_b12.html> [accessed Aug 5, 2016].
253. Emisphere Technologies, Inc. Available URL: < http://www.emisphere.com/novartis_pharma_ag.html> [accessed Aug 5, 2016].
254. Emisphere Technology, Inc. Available URL: < http://www.emisphere.com/oral_recombinant_ph.html> [accessed Aug 5, 2016].
255. Tillman, L.G., Geary, R.S., Hardee, G.E., Oral delivery of antisense oligonucleotides in man. J Pharm Sci 97 (2008), 225–236.
256. Kidron M. Methods and compositions for oral administration of proteins. Google Patents; 2007.
257. Oramed Pharmaceuticals Inc. Available URL: < http://www.oramed.com/pipeline/> [accessed Aug 5, 2016].
258. Chiasma, Inc. Available from URL: < http://www.chiasmapharma.com/octreotide-capsules> [accessed Aug 5, 2016].
259. Luzio, S.D., Dunseath, G., Lockett, A., Broke-Smith, T.P., New, R.R., Owens, D.R., The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. Diabetes Obes Metab 12 (2010), 82–87.
260. Choonara, B.F., Choonara, Y.E., Kumar, P., Bijukumar, D., du Toit, L.C., Pillay, V., A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules. Biotechnol Adv 32 (2014), 1269–1282.
261. Bernkop-Schnurch, A., The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J Control Release: Off J Control Release Soc 52 (1998), 1–16.
262. Moroz, E., Matoori, S., Leroux, J.C., Oral delivery of macromolecular drugs: where we are after almost 100 years of attempts. Adv Drug Deliv Rev 101 (2016), 108–121.
263. Marschutz, M.K., Bernkop-Schnurch, A., Oral peptide drug delivery: polymer-inhibitor conjugates protecting insulin from enzymatic degradation in vitro. Biomaterials 21 (2000), 1499–1507.
264. Werle, M., Loretz, B., Entstrasser, D., Foger, F., Design and evaluation of a chitosan-aprotinin conjugate for the peroral delivery of therapeutic peptides and proteins susceptible to enzymatic degradation. J Drug Target 15 (2007), 327–333.
265. Welling, S.H., Hubalek, F., Jacobsen, J., Brayden, D.J., Rahbek, U.L., Buckley, S.T., The role of citric acid in oral peptide and protein formulations: relationship between calcium chelation and proteolysis inhibition. Eur J Pharm Biopharm: Off J Arbeitsgemeinschaft Pharmazeutische Verfahrenstechnik eV 86 (2014), 544–551.
266. Friedman, D.I., Amidon, G.L., Oral absorption of peptides: influence of pH and inhibitors on the intestinal hydrolysis of leu-enkephalin and analogues. Pharm Res 8 (1991), 93–96.
267. Enteris BioPharma, Inc. Available from URL: < http://enterisbiopharma.com/oral-drug-delivery/mechanism/> [accessed Aug 5, 2016].
268. Crotts G, Ghebre-Sellassie I, Sheth A. Oral peptide pharmaceutical dosage form and method of production. Google Patents; 2002.
269. Tarsa's Oral Calcitonin—TBRIA™. Available from URL: < http://tarsatherapeutics.com/products/tbria/> [accessed Aug 18, 2016].
270. Austin, R.H., Lim, S.F., The Sackler Colloquium on promises and perils in nanotechnology for medicine. Proc Natl Acad Sci USA 105 (2008), 17217–17221.
271. Nel, A., Xia, T., Madler, L., Li, N., Toxic potential of materials at the nanolevel. Science 311 (2006), 622–627.
272. Sharifi, S., Behzadi, S., Laurent, S., Forrest, M.L., Stroeve, P., Mahmoudi, M., Toxicity of nanomaterials. Chem Soc Rev 41 (2012), 2323–2343.
273. Klaine, S.J., Koelmans, A.A., Horne, N., Carley, S., Handy, R.D., Kapustka, L., et al. Paradigms to assess the environmental impact of manufactured nanomaterials. Environ Toxicol Chem 31 (2012), 3–14.
274. Oberdörster, G., Oberdörster, E., Oberdörster, J., Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 113 (2005), 823–839.
275. Arora, S., Rajwade, J.M., Paknikar, K.M., Nanotoxicology and in vitro studies: the need of the hour. Toxicol Appl Pharmacol 258 (2012), 151–165.
276. Alkilany, A.M., Mahmoud, N.N., Hashemi, F., Hajipour, M.J., Farvadi, F., Mahmoudi, M., Misinterpretation in nanotoxicology: a personal perspective. Chem Res Toxicol 29 (2016), 943–948.
277. Elsabahy, M., Wooley, K.L., Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev 41 (2012), 2545–2561.
278. Bianco, A., Kostarelos, K., Prato, M., Making carbon nanotubes biocompatible and biodegradable. Chem Commun (Camb) 47 (2011), 10182–10188.
279. Liu, K., Zhang, J.-J., Cheng, F.-F., Zheng, T.-T., Wang, C., Zhu, J.-J., Green and facile synthesis of highly biocompatible graphene nanosheets and its application for cellular imaging and drug delivery. J Mater Chem 21 (2011), 12034–12040.
280. Nurunnabi, M., Khatun, Z., Huh, K.M., Park, S.Y., Lee, D.Y., Cho, K.J., et al. In vivo biodistribution and toxicology of carboxylated graphene quantum dots. ACS Nano 7 (2013), 6858–6867.
281. Shahbazi, M.A., Hamidi, M., Makila, E.M., Zhang, H., Almeida, P.V., Kaasalainen, M., et al. The mechanisms of surface chemistry effects of mesoporous silicon nanoparticles on immunotoxicity and biocompatibility. Biomaterials 34 (2013), 7776–7789.
282. Food and Drug Administration. Combination product definition. Available at URL: < http://www.fda.gov/CombinationProducts/AboutCombinationProducts/ucm118332.htm> [accessed Jul 27, 2016].
283. Kulkarni, S.A., Feng, S.S., Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery. Pharm Res 30 (2013), 2512–2522.
284. Yu, T., Greish, K., McGill, L.D., Ray, A., Ghandehari, H., Influence of geometry, porosity, and surface characteristics of silica nanoparticles on acute toxicity: their vasculature effect and tolerance threshold. ACS Nano 6 (2012), 2289–2301.
285. Luyts, K., Napierska, D., Nemery, B., Hoet, P.H., How physico-chemical characteristics of nanoparticles cause their toxicity: complex and unresolved interrelations. Environ Sci Process Impacts 15 (2013), 23–38.
286. Podila, R., Brown, J.M., Toxicity of engineered nanomaterials: a physicochemical perspective. J Biochem Biophys Methods 27 (2013), 50–55.
287. Fu, C., Liu, T., Li, L., Liu, H., Chen, D., Tang, F., The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes. Biomaterials 34 (2013), 2565–2575.
288. Bansal, A.K., Excipients used in nano-technology assisted drug delivery systems. J Excip Food Chem 5 (2014), 173–176.
289. Osterberg, R.E., Demerlis, C.C., Hobson, D.W., McGovern, T.J., Trends in excipient safety evaluation. Int J Toxicol 30 (2011), 600–610.
290. Elder, D.P., Kuentz, M., Holm, R., Pharmaceutical excipients – quality, regulatory and biopharmaceutical considerations. Eur J Pharm Sci 87 (2016), 88–99.
291. Hoet, P., Legiest, B., Geys, J., Nemery, B., Do nanomedicines require novel safety assessments to ensure their safety for long-term human use?. Drug Saf 32 (2009), 625–636.
292. Bartlett, J.A., Brewster, M., Brown, P., Cabral-Lilly, D., Cruz, C.N., David, R., et al. Summary report of PQRI Workshop on Nanomaterial in Drug Products: current experience and management of potential risks. AAPS J 17 (2015), 44–64.
293. Kang, H., Mintri, S., Menon, A.V., Lee, H.Y., Choi, H.S., Kim, J., Pharmacokinetics, pharmacodynamics and toxicology of theranostic nanoparticles. Nanoscale 7 (2015), 18848–18862.
294. Griffin, B.T., Guo, J., Presas, E., Donovan, M.D., Alonso, M.J., O'Driscoll, C.M., Pharmacokinetic, pharmacodynamic and biodistribution following oral administration of nanocarriers containing peptide and protein drugs. Adv Drug Deliv Rev 106:Part B (2016), 367–380.
295. Satalkar, P., Elger, B.S., Shaw, D.M., Defining nano, nanotechnology and nanomedicine: why should it matter?. Sci Eng Ethics, 2015, 10.1007/s11948-015-9705-6.
296. Sadrieh, N., Espandiari, P., Nanotechnology and the FDA: what are the scientific and regulatory considerations for products containing nanomaterials. Nanotech Law Bus, 3, 2006, 339.
297. Tyner, K.M., Zou, P., Yang, X., Zhang, H., Cruz, C.N., Lee, S.L., Product quality for nanomaterials: current U.S. experience and perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol 7 (2015), 640–654.
298. Hamburg, M.A., Science and regulation. FDA's approach to regulation of products of nanotechnology. Science 336 (2012), 299–300.
299. US Food and Drug Administration. Guidance for industry. Considering whether an FDA-regulated product involves the application of nanotechnology. Silver Spring, MD; 2014. Available from URL: < http://www.fda.gov/RegulatoryInformation/Guidances/ucm257698.htm> [accessed Jul 26, 2016].
300. US Food and Drug Administration. Liposome drug products: chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability; and labeling documentation. Revision 1; 2015. Available from URL: < http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070570.pdf> [accessed Aug 1, 2016].
301. US Food and Drug Administration. Draft guidance on ferumoxytol. Available at URL: < http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM333051> [accessed Jul 27, 2016].
302. Bawa, R., Regulating nanomedicine – can the FDA handle it?. Curr Drug Deliv 8 (2011), 227–234.
303. European Medicines Agency. Multidisciplinary: nanomedicines. < http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000564.jsp&mid=WC0b01ac05806403e0> [accessed Jul 26, 2016].
304. de la Ossa DHP. Nanomedicines: EMA experience and perspective. In: EuroNanoForum 2015. Riga, Latvia; 2015.
305. US Food and Drug Administration. Drugs@FDA – FDA approved drug products. Available from URL: < http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm> [accessed Aug 3, 2016].
306. European Medicines Agency. European public assessment reports. Available from URL: < http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d125> [accessed Aug 2, 2016].
307. Tinkle, S., McNeil, S.E., Muhlebach, S., Bawa, R., Borchard, G., Barenholz, Y.C., et al. Nanomedicines: addressing the scientific and regulatory gap. Ann N Y Acad Sci 1313 (2014), 35–56.
308. Guo, J.W., Lee, Y.H., Huang, H.W., Tzou, M.C., Wang, Y.J., Tsai, J.C., Development of Taiwan's strategies for regulating nanotechnology-based pharmaceuticals harmonized with international considerations. Int J Nanomed 9 (2014), 4773–4783.
309. Jiang, W., Lionberger, R., Yu, L.X., In vitro and in vivo characterizations of PEGylated liposomal doxorubicin. Bioanalysis 3 (2011), 333–344.
310. Bowman, D.M., Gatof, J., Reviewing the regulatory barriers for nanomedicine: global questions and challenges. Nanomedicine (Lond) 10 (2015), 3275–3286.
311. European Medicines Agency & Food and Drug Administration. General principles. EMEA-FDA parallel scientific advice; 2009. Available from URL: < http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500014868> [accessed Jul 26, 2016].
312. Sainz, V., Conniot, J., Matos, A.I., Peres, C., Zupancic, E., Moura, L., et al. Regulatory aspects on nanomedicines. Biochem Biophys Res Commun 468 (2015), 504–510.
313. 2015 – a record year for antibody product approvals, but not for biopharmaceuticals overall. Available from URL: < http://www.bioprocessblog.com/archives/807> [accessed Aug 16, 2016].
314. Chou, L.Y.T., Ming, K., Chan, W.C.W., Strategies for the intracellular delivery of nanoparticles. Chem Soc Rev 40 (2011), 233–245.
315. Jazayeri, M.H., Amani, H., Pourfatollah, A.A., Pazoki-Toroudi, H., Sedighimoghaddam, B., Various methods of gold nanoparticles (GNPs) conjugation to antibodies. Sens Biosens Res 9 (2016), 17–22.
316. Hermanson GT. Bioconjugation techniques. 3rd ed. Elsevier; 2013. p. 558.
317. Florence, A.T., Nanoparticle uptake by the oral route: fulfilling its potential?. Drug Discov Today: Technol 2 (2005), 75–81.
318. Pan, Y., Li, Y.J., Zhao, H.Y., Zheng, J.M., Xu, H., Wei, G., et al. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm 249 (2002), 139–147.
319. Mukhopadhyay, P., Sarkar, K., Chakraborty, M., Bhattacharya, S., Mishra, R., Kundu, P.P., Oral insulin delivery by self-assembled chitosan nanoparticles: in vitro and in vivo studies in diabetic animal model. Mater Sci Eng C: Mater Biol Appl 33 (2013), 376–382.
320. Ma, Z., Lim, T.M., Lim, L.Y., Pharmacological activity of peroral chitosan-insulin nanoparticles in diabetic rats. Int J Pharm 293 (2005), 271–280.
321. Yin, L., Ding, J., He, C., Cui, L., Tang, C., Yin, C., Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials 30 (2009), 5691–5700.
322. Bayat, A., Dorkoosh, F.A., Dehpour, A.R., Moezi, L., Larijani, B., Junginger, H.E., et al. Nanoparticles of quaternized chitosan derivatives as a carrier for colon delivery of insulin: ex vivo and in vivo studies. Int J Pharm 356 (2008), 259–266.
323. Rekha, M.R., Sharma, C.P., Synthesis and evaluation of lauryl succinyl chitosan particles towards oral insulin delivery and absorption. J Control Release 135 (2009), 144–151.
324. Bowman, K., Leong, K.W., Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomed 1 (2006), 117–128.
325. Amidi, M., Mastrobattista, E., Jiskoot, W., Hennink, W.E., Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev 62 (2010), 59–82.
326. Chalasani, K.B., Russell-Jones, G.J., Yandrapu, S.K., Diwan, P.V., Jain, S.K., A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. J Control Release 117 (2007), 421–429.
327. Sarmento, B., Ribeiro, A., Veiga, F., Ferreira, D., Neufeld, R., Oral bioavailability of insulin contained in polysaccharide nanoparticles. Biomacromol 8 (2007), 3054–3060.
328. Sarmento, B., Ribeiro, A., Veiga, F., Ferreira, D., Development and characterization of new insulin containing polysaccharide nanoparticles. Colloids Surf B: Biointerfaces 53 (2006), 193–202.
329. Sarmento, B., Ribeiro, A., Veiga, F., Sampaio, P., Neufeld, R., Ferreira, D., Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm Res 24 (2007), 2198–2206.
330. Sarmento, B., Ribeiro, A.J., Veiga, F., Ferreira, D.C., Neufeld, R.J., Insulin-loaded nanoparticles are prepared by alginate ionotropic pre-gelation followed by chitosan polyelectrolyte complexation. J Nanosci Nanotechnol 7 (2007), 2833–2841.
331. Woitiski, C.B., Neufeld, R.J., Veiga, F., Carvalho, R.A., Figueiredo, I.V., Pharmacological effect of orally delivered insulin facilitated by multilayered stable nanoparticles. Eur J Pharm Sci 41 (2010), 556–563.
332. Woitiski, C.B., Sarmento, B., Carvalho, R.A., Neufeld, R.J., Veiga, F., Facilitated nanoscale delivery of insulin across intestinal membrane models. Int J Pharm 412 (2011), 123–131.
333. Woitiski, C.B., Neufeld, R.J., Soares, A.F., Figueiredo, I.V., Veiga, F.J., Carvalho, R.A., Evaluation of hepatic glucose metabolism via gluconeogenesis and glycogenolysis after oral administration of insulin nanoparticles. Drug Dev Ind Pharm 38 (2012), 1441–1450.
334. Coppi, G., Iannuccelli, V., Sala, N., Bondi, M., Alginate microparticles for polymyxin B Peyer's patches uptake: microparticles for antibiotic oral administration. J Microencapsul 21 (2004), 829–839.
335. Suksamran, T., Opanasopit, P., Rojanarata, T., Ngawhirunpat, T., Ruktanonchai, U., Supaphol, P., Biodegradable alginate microparticles developed by electrohydrodynamic spraying techniques for oral delivery of protein. J Microencapsul 26 (2009), 563–570.
336. Lin, Y.H., Mi, F.L., Chen, C.T., Chang, W.C., Peng, S.F., Liang, H.F., et al. Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery. Biomacromol 8 (2007), 146–152.
337. Su, F.Y., Lin, K.J., Sonaje, K., Wey, S.P., Yen, T.C., Ho, Y.C., et al. Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery. Biomaterials 33 (2012), 2801–2811.
338. Han, L., Zhao, Y., Yin, L., Li, R., Liang, Y., Huang, H., et al. Insulin-loaded pH-sensitive hyaluronic acid nanoparticles enhance transcellular delivery. AAPS PharmSciTech 13 (2012), 836–845.
339. Xiong, X.Y., Li, Q.H., Li, Y.P., Guo, L., Li, Z.L., Gong, Y.C., Pluronic P85/poly(lactic acid) vesicles as novel carrier for oral insulin delivery. Colloids Surf B: Biointerfaces 111 (2013), 282–288.
340. Xiong, X.Y., Li, Y.P., Li, Z.L., Zhou, C.L., Tam, K.C., Liu, Z.Y., et al. Vesicles from Pluronic/poly(lactic acid) block copolymers as new carriers for oral insulin delivery. J Control Release 120 (2007), 11–17.
341. Sharma, G., van der Walle, C.F., Ravi Kumar, M.N., Antacid co-encapsulated polyester nanoparticles for peroral delivery of insulin: development, pharmacokinetics, biodistribution and pharmacodynamics. Int J Pharm 440 (2013), 99–110.
342. Yang, J., Sun, H., Song, C., Preparation, characterization and in vivo evaluation of pH-sensitive oral insulin-loaded poly(lactic-co-glycolicacid) nanoparticles. Diabetes Obes Metab 14 (2012), 358–364.
343. Sun, S., Liang, N., Piao, H., Yamamoto, H., Kawashima, Y., Cui, F., Insulin-S.O (sodium oleate) complex-loaded PLGA nanoparticles: formulation, characterization and in vivo evaluation. J Microencapsul 27 (2010), 471–478.
344. Cui, F., Shi, K., Zhang, L., Tao, A., Kawashima, Y., Biodegradable nanoparticles loaded with insulin–phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. J Control Release 114 (2006), 242–250.
345. Cui, F.D., Tao, A.J., Cun, D.M., Zhang, L.Q., Shi, K., Preparation of insulin loaded PLGA-Hp55 nanoparticles for oral delivery. J Pharm Sci 96 (2007), 421–427.
346. Carino, G.P., Jacob, J.S., Mathiowitz, E., Nanosphere based oral insulin delivery. J Control Release 65 (2000), 261–269.
347. Jain, S., Rathi, V.V., Jain, A.K., Das, M., Godugu, C., Folate-decorated PLGA nanoparticles as a rationally designed vehicle for the oral delivery of insulin. Nanomedicine (Lond) 7 (2012), 1311–1337.
348. Liu, X., Liu, C., Zhang, W., Xie, C., Wei, G., Lu, W., Oligoarginine-modified biodegradable nanoparticles improve the intestinal absorption of insulin. Int J Pharm 448 (2013), 159–167.
349. Zhu, S., Chen, S., Gao, Y., Guo, F., Li, F., Xie, B., et al. Enhanced oral bioavailability of insulin using PLGA nanoparticles co-modified with cell-penetrating peptides and Engrailed secretion peptide (Sec). Drug Deliv 23 (2016), 1980–1991.
350. Sharma, R., Gupta, U., Garg, N.K., Tyagi, R.K., Jain, N.K., Surface engineered and ligand anchored nanobioconjugate: an effective therapeutic approach for oral insulin delivery in experimental diabetic rats. Colloids Surf B: Biointerfaces 127 (2015), 172–181.
351. Jain, A., Jain, S.K., L-Valine appended PLGA nanoparticles for oral insulin delivery. Acta Diabetol 52 (2015), 663–676.
352. Cetin, M., Aktas, M.S., Vural, I., Ozturk, M., Salmon calcitonin-loaded Eudragit(R) and Eudragit(R)-PLGA nanoparticles: in vitro and in vivo evaluation. J Microencapsul 29 (2012), 156–166.
353. Semete, B., Booysen, L.I., Kalombo, L., Venter, J.D., Katata, L., Ramalapa, B., et al. In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles. Toxicol Appl Pharmacol 249 (2010), 158–165.
354. Sang Yoo, H., Gwan, Park T., Biodegradable nanoparticles containing protein-fatty acid complexes for oral delivery of salmon calcitonin. J Pharm Sci 93 (2004), 488–495.
355. Damge, C., Maincent, P., Ubrich, N., Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J Control Release 117 (2007), 163–170.
356. Damge, C., Socha, M., Ubrich, N., Maincent, P., Poly(epsilon-caprolactone)/eudragit nanoparticles for oral delivery of aspart-insulin in the treatment of diabetes. J Pharm Sci 99 (2010), 879–889.
357. Socha, M., Sapin, A., Damge, C., Maincent, P., Influence of polymers ratio on insulin-loaded nanoparticles based on poly-epsilon-caprolactone and Eudragit RS for oral administration. Drug Deliv 16 (2009), 430–436.
358. Deutel, B., Greindl, M., Thaurer, M., Bernkop-Schnurch, A., Novel insulin thiomer nanoparticles: in vivo evaluation of an oral drug delivery system. Biomacromol 9 (2008), 278–285.
359. Foss, A.C., Goto, T., Morishita, M., Peppas, N.A., Development of acrylic-based copolymers for oral insulin delivery. Eur J Pharm Biopharm 57 (2004), 163–169.
360. Perera, G., Greindl, M., Palmberger, T.F., Bernkop-Schnurch, A., Insulin-loaded poly(acrylic acid)-cysteine nanoparticles: stability studies towards digestive enzymes of the intestine. Drug Deliv 16 (2009), 254–260.
361. Zhang, Y., Wu, X., Meng, L., Ai, R., Qi, N., He, H., et al. Thiolated Eudragit nanoparticles for oral insulin delivery: preparation, characterization and in vivo evaluation. Int J Pharm 436 (2012), 341–350.
362. Bernkop-Schnürch, A., Kast, C.E., Guggi, D., Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: thiomer/GSH systems. J Control Release 93 (2003), 95–103.
363. Garcia-Fuentes, M., Torres, D., Alonso, M.J., New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int J Pharm 296 (2005), 122–132.
364. Christophersen, P.C., Zhang, L., Yang, M., Nielsen, H.M., Mullertz, A., Mu, H., Solid lipid particles for oral delivery of peptide and protein drugs I – elucidating the release mechanism of lysozyme during lipolysis. Eur J Pharm Biopharm 85 (2013), 473–480.
365. Martins, S., Silva, A.C., Ferreira, D.C., Souto, E.B., Improving oral absorption of Salmon calcitonin by trimyristin lipid nanoparticles. J Biomed Nanotechnol 5 (2009), 76–83.
366. Yang, R., Gao, R., Li, F., He, H., Tang, X., The influence of lipid characteristics on the formation, in vitro release, and in vivo absorption of protein-loaded SLN prepared by the double emulsion process. Drug Dev Ind Pharm 37 (2011), 139–148.
367. Yang, R., Gao, R.C., Cai, C.F., Xu, H., Li, F., He, H.B., et al. Preparation of gel-core-solid lipid nanoparticle: a novel way to improve the encapsulation of protein and peptide. Chem Pharm Bull (Tokyo) 58 (2010), 1195–1202.
368. Hu, F.Q., Hong, Y., Yuan, H., Preparation and characterization of solid lipid nanoparticles containing peptide. Int J Pharm 273 (2004), 29–35.
369. Moghassemi, S., Parnian, E., Hakamivala, A., Darzianiazizi, M., Vardanjani, M.M., Kashanian, S., et al. Uptake and transport of insulin across intestinal membrane model using trimethyl chitosan coated insulin niosomes. Mater Sci Eng, C 46 (2015), 333–340.
370. Zhang, X., Qi, J., Lu, Y., Hu, X., He, W., Wu, W., Enhanced hypoglycemic effect of biotin-modified liposomes loading insulin: effect of formulation variables, intracellular trafficking, and cytotoxicity. Nanoscale Res Lett, 9, 2014, 185.
371. Zhang, X., Qi, J., Lu, Y., He, W., Li, X., Wu, W., Biotinylated liposomes as potential carriers for the oral delivery of insulin. Nanomedicine 10 (2014), 167–176.
372. Agrawal, A.K., Harde, H., Thanki, K., Jain, S., Improved stability and antidiabetic potential of insulin containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration. Biomacromol 15 (2014), 350–360.
373. Niu, Z., Conejos-Sanchez, I., Griffin, B.T., O'Driscoll, C.M., Alonso, M.J., Lipid-based nanocarriers for oral peptide delivery. Adv Drug Deliv Rev, 2016.
374. Niebel, W., Walkenbach, K., Béduneau, A., Pellequer, Y., Lamprecht, A., Nanoparticle-based clodronate delivery mitigates murine experimental colitis. J Control Release 160 (2012), 659–665.
375. Han, H.-K., Shin, H.-J., Ha, D.H., Improved oral bioavailability of alendronate via the mucoadhesive liposomal delivery system. Eur J Pharm Sci 46 (2012), 500–507.
376. Coco, R., Plapied, L., Pourcelle, V., Jérôme, C., Brayden, D.J., Schneider, Y.-J., et al. Drug delivery to inflamed colon by nanoparticles: comparison of different strategies. Int J Pharm 440 (2013), 3–12.
377. Tobio, M., Sanchez, A., Vila, A., Soriano, I.I., Evora, C., Vila-Jato, J.L., et al. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surf, B 18 (2000), 315–323.
378. Fricker, G., Kromp, T., Wendel, A., Blume, A., Zirkel, J., Rebmann, H., et al. Phospholipids and lipid-based formulations in oral drug delivery. Pharm Res 27 (2010), 1469–1486.
379. Cui, F., Qian, F., Yin, C., Preparation and characterization of mucoadhesive polymer-coated nanoparticles. Int J Pharm 316 (2006), 154–161.
380. Wilcox, M.D., Van, Rooij L.K., Chater, P.I., Pereira de Sousa, I., Pearson, J.P., The effect of nanoparticle permeation on the bulk rheological properties of mucus from the small intestine. Eur J Pharm Biopharm 96 (2015), 484–487.
381. Shan, W., Zhu, X., Liu, M., Li, L., Zhong, J., Sun, W., et al. Overcoming the diffusion barrier of mucus and absorption barrier of epithelium by self-assembled nanoparticles for oral delivery of insulin. ACS Nano 9 (2015), 2345–2356.
382. Sajeesh, S., Sharma, C.P., Mucoadhesive hydrogel microparticles based on poly (methacrylic acid-vinyl pyrrolidone)-chitosan for oral drug delivery. Drug Deliv 18 (2011), 227–235.
383. Sonia, T.A., Sharma, C.P., In vitro evaluation of quaternized polydimethylaminoethylmethacrylate sub-microparticles for oral insulin delivery. J Biomater Appl 28 (2013), 62–73.
384. Abouelmagd, S.A., Ku, Y.J., Yeo, Y., Low molecular weight chitosan-coated polymeric nanoparticles for sustained and pH-sensitive delivery of paclitaxel. J Drug Target 23 (2015), 725–735.
385. Izadi, Z., Divsalar, A., Saboury, A.A., Sawyer, L., β-Lactoglobulin–pectin nanoparticle-based oral drug delivery system for potential treatment of colon cancer. Chem Biol Drug Des 88 (2016), 209–216.
386. Makhlof, A., Tozuka, Y., Takeuchi, H., pH-sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model. Eur J Pharm Biopharm 72 (2009), 1–8.
387. Prasad, S., Dangi, J.S., Development and characterization of pH responsive polymeric nanoparticles of SN-38 for colon cancer. Artif Cells Nanomed Biotechnol, 2015, 1–11.
388. Wang, Y., Qin, F., Tan, H., Zhang, Y., Jiang, M., Lu, M., et al. PH-responsive glycol chitosan-cross-linked carboxymethyl-beta-cyclodextrin nanoparticles for controlled release of anticancer drugs. Int J Nanomed 10 (2015), 7359–7369.
389. Gao, H., Yang, Z., Zhang, S., Cao, S., Shen, S., Pang, Z., et al. Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci Rep, 3, 2013, 2534.
390. Pridgen, E.M., Alexis, F., Kuo, T.T., Levy-Nissenbaum, E., Karnik, R., Blumberg, R.S., et al. Transepithelial transport of Fc-targeted nanoparticles by the neonatal Fc receptor for oral delivery. Sci Transl Med, 2013, 5 213ra167-213ra167.
391. Xiao, B., Laroui, H., Ayyadurai, S., Viennois, E., Charania, M.A., Zhang, Y., et al. Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-α RNA interference for IBD therapy. Biomaterials 34 (2013), 7471–7482.
392. Laroui, H., Viennois, E., Xiao, B., Canup, B.S., Geem, D., Denning, T.L., et al. Fab'-bearing siRNA TNFalpha-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis. J Control Release: Off J Control Release Soc 186 (2014), 41–53.
393. Xiao, B., Laroui, H., Viennois, E., Ayyadurai, S., Charania, M.A., Zhang, Y., et al. Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterology, 2014, 146 1289-300.e1-19.
394. Wilson, D.S., Dalmasso, G., Wang, L., Sitaraman, S.V., Merlin, D., Murthy, N., Orally delivered thioketal nanoparticles loaded with TNF-α–siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater 9 (2010), 923–928.
395. Zheng, C., Zhang, X.G., Sun, L., Zhang, Z.P., Li, C.X., Biodegradable and redox-responsive chitosan/poly(L-aspartic acid) submicron capsules for transmucosal delivery of proteins and peptides. J Mater Sci – Mater Med 24 (2013), 931–939.